Matching-Adjusted Indirect Comparisons (Maics) of Iberdomide, Daratumumab (DARA), and Dexamethasone (Iberdd) Versus Regimens Containing DARA and Imids in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-299; Pres time: Sep 25, 2026; "In the ongoing phase 3 randomized controlled trial EXCALIBER-RRMM, IberDd demonstrated significantly higher MRDneg CR in comparison with DARA + bortezomib + dexamethasone (DEX) (DVd) in RRMM; however, head-to-head comparative evidence versus other DARA-based standard regimens is unavailable. Two unanchored MAICs were therefore conducted to estimate the comparative efficacy of IberDd versus DARA + lenalidomide + DEX (DRd) and DARA + pomalidomide + DEX (DPd)... Across 2 independent unanchored MAICs, IberDd was associated with significantly [REDACTED] MRDneg CR rates versus commonly used DARA-based regimens in patients with RRMM after ≥1 prior line. Findings were robust across sensitivity analyses and support the clinical efficacy of IberDd, with potential implications for RRMM treatment paradigms."
Hematological Malignancies • Multiple Myeloma • IKZF1
|
|
Ola Landgren1; Maria Gavriatopoulou2; Hang Quach3; Fredrik Schjesvold4; Vania Hungria5; MaríaVictoria Mateos6; Nisha S. Joseph7; Chengcheng Fu8; Saulius Girnius9; Kevin Towle10; Jenny Chen10; Sichen Liu10; Elissa Min10; Ying Qiu11; Paulo Maciag11; Gabriela Hernandez Rivera12; Yu-Hsuan Shih11; Sagar Lonial7
|